IL‐17 alters the composition of tumor‐infiltrating leukocytes (TILs)6, 7 and reduces the sensitivity to chemotherapy8 and anti‐vascular endothelial growth factor (VEGF) therapy.8 This evidence concerns the gene VEGFA and neoplasm.